Stephens Inc’s Supernus Pharmaceuticals SUPN Stock Holding History

Stephens Inc’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-145	Closed	-$5K	–	1208
2018 Q4	$5K	Buy	+145	New	+$6.24K	﹤0.01%	1101

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stephens Inc's SUPN Position: Q1 2019 in Review

Stephens Inc sold out of Supernus Pharmaceuticals (SUPN) in Q1 2019, closing a stake of 145 shares — an estimated $5K sold.

Stephens Inc first reported a position in SUPN in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

Stephens Inc reported no remaining Supernus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Stephens Inc sold 145 Supernus Pharmaceuticals shares in Q1 2019, an estimated $5K.
Stephens Inc first reported a position in Supernus Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Stephens Inc's Supernus Pharmaceuticals position peaked at $5K in Q4 2018.
289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Stephens Inc's 13F filing for Q1 2019, filed 3 May 2019.